l 012

L 012 is a bioactive chemical.

L 012 sodium salt, a luminol analogue, is a widely used chemiluminescent (CL) probe for active oxygen and active nitrogen. L 012 sodium salt is widely used to detect the superoxides (O2•−) derived from NADPH oxidase (Nox) to find Nox inhibitors.

2-Amino-4,7-dihydro-5H-thieno[2,3-c]pyridine-3,6-dicarboxylic acid 6-tert butyl ester 3-ethyl ester ,with CAS No. 193537-14-3, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. 2-Amino-4,7-dihydro-5H-thieno[2,3-c]pyridine-3,6-dicarboxylic acid 6-tert butyl ester 3-ethyl ester provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

7-Amino-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one ,with CAS No. 22245-92-7, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. 7-Amino-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound FL0120, with CAS No. 22246-76-0, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound FL0120 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound FL0123, with CAS No. 635712-88-8, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound FL0123 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound FL0124, with CAS No. 1190971-73-3, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound FL0124 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound FL0125, with CAS No. 179950-69-7, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound FL0125 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound FL0126, with CAS No. 5444-61-1, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound FL0126 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound FL0127, with CAS No. 40769-81-1, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound FL0127 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound FL0128, with CAS No. 887625-09-4, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound FL0128 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Tapencarium (RZL-012) is a serine/threonine kinase inhibitor that reduces subcutaneous fat volume. It holds potential for research into fat-related conditions, including Dercum's disease and cosmetic uses.

MCL0129, a selective and non-peptidergic melanocortin 4 (MC4) receptor antagonist, is a potential treatment for cachexia.

BXL0124 is a gemini vitamin D analog which targets CD44-STAT3 signaling and inhibits breast cancer invasion.

16:0-18:1 Diether PG is a type of glycerophospholipid where a hexadecyl chain and an octadecenyl chain are connected via ether bonds to the glycerol backbone at the sn-1 and sn-2 positions, respectively. 16:0-18:1 Diether PG is utilized in the preparation of liposomes.

Palm oil is a type of palm oil that can serve as a carrier for active molecules.

DSPE-PEG2000-Azide ammonium is a lipid-based azide compound used in forming micelles for nanoparticle drug delivery. It serves as a click chemistry reagent and includes an azide group that reacts with molecules containing an alkyne group through a copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc). Additionally, it can engage in a strain-promoted azide-alkyne cycloaddition (SPAAC) with molecules containing DBCO or BCN groups.

08:0 PI ammonium is a glycerophospholipid featuring a head group that carries a cyclohexanol moiety.

C17 Lyso PAF (1-O-Heptadecyl-2-hydroxy-sn-glycero-3-phosphocholine) acts as a precursor and metabolite of 1-O-Heptadecyl-2-acetyl-sn-glycero-3-phosphocholine (C17:0 PAF).

Lipid 11 (Compound Lipid 1) is a cationic lipid designed for nucleic acid delivery. It forms lipid nanoparticles (LNPs) through electrostatic interactions with nucleic acids, such as ceDNA. By using its cationic amine groups, Lipid 11 complexes with negatively charged nucleic acids, enabling cellular uptake and release of the nucleic acid cargo. Lipid 11 shows potential for use in the development of gene therapy drug delivery systems.

Lipid I97 is an ionizable cationic lipid derived from vitamin B5 with a pKa of 6.23. It has been utilized in the formation of lipid nanoparticles (LNPs) for mRNA delivery in vivo. In mice, LNPs with lipid I97 encapsulating luciferase mRNA specifically accumulate in the spleen and lymph nodes. Additionally, LNPs containing lipid I97 with mRNA encoding hemagglutinin A trigger the production of IgG1 and IgG2 in mice.

E10i-494 is an ionizable cationic branched endosomal disruptor (BEND) lipid utilized in the formation of lipid nanoparticles (LNPs) for mRNA delivery in vitro. These LNPs, encapsulating mCherry or luciferase mRNA, trigger the expression of mCherry or luciferase in T cells.

TCL065, an ionizable cationic lipid (pKa = 6.3), is utilized in the creation of lipid nanoparticles (LNPs) for the delivery of mRNA and single-guide RNA (sgRNA) both in vitro and in vivo. When LNPs with TCL065 encapsulate sgRNA targeting the donor site of dystrophin exon 45, along with those targeting the splicing acceptor site of dystrophin exon 45, dystrophin expression is restored in myoblasts derived from induced-pluripotent stem (iPS) cells from Duchenne muscular dystrophy (DMD) patients. Additionally, TCL065-containing LNPs encapsulating mRNA encoding Cas9 nuclease, combined with those containing sgRNA targeting the Rosa26 locus, have been applied for CRISPR-mediated gene editing in mouse gastrocnemius muscle.

IAJD97 is an ionizable amphiphilic Janus dendrimer (pKa = 6.46) employed in creating dendrosome nanoparticles (DNPs) for in vivo mRNA delivery. DNPs made from IAJD97 and containing mRNA for luciferase preferentially target the lymph nodes, spleen, and lungs rather than the liver and heart in mice.